Tokyo, Japan

Fumitaka Kamachi

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Fumitaka Kamachi: Innovator in Liver Cancer Treatment

Introduction

Fumitaka Kamachi is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical research, particularly in the treatment of liver cancer associated with nonalcoholic steatohepatitis (NASH). With a total of 2 patents, his work is paving the way for innovative therapeutic approaches.

Latest Patents

Kamachi's latest patents focus on the use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer. This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists that are useful in treating NASH-associated liver cancer in humans or animals. The method involves administering one or more of Compound A, Compound B, or Compound C, or their pharmaceutically acceptable salts, as the EP4 antagonist(s). Additionally, the method may include a pharmaceutical composition comprising the EP4 antagonist, along with one or more other active agents and/or therapies.

Career Highlights

Fumitaka Kamachi is currently associated with Askat Inc., where he continues to develop innovative solutions in the medical field. His expertise and dedication to research have positioned him as a key figure in advancing treatments for liver cancer.

Collaborations

Kamachi collaborates with talented professionals in his field, including Naoko Ohtani and Tze Mun Loo. Their combined efforts contribute to the ongoing research and development of effective therapies.

Conclusion

Fumitaka Kamachi's work in the development of EP4 receptor antagonists represents a significant advancement in the treatment of NASH-associated liver cancer. His contributions are vital to the ongoing fight against this challenging disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…